|Bid||3.6100 x 1400|
|Ask||3.6800 x 800|
|Day's Range||3.5220 - 3.6600|
|52 Week Range||3.2300 - 8.8500|
|Beta (5Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.50|
Subscribe to Yahoo Finance Plus to view Fair Value for MESO
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
The big shareholder groups in Mesoblast Limited ( ASX:MSB ) have power over the company. Institutions will often hold...
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2022. Financial highlights Net cash usage for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 million compared with US$25.8 million in the comparativ